Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.15 is 21% below its 5-year average of 0.19, around the middle of its 5-year range (0.06–0.33).
As of the fiscal period ended Tuesday, June 30, 2026. 32.55% below its 12-month average of 0.22.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.15.
DEBT TO EQUITY RATIO
0.15
DEBT TO EQUITY RATIO AVG TTM
0.22
DEBT TO EQUITY RATIO AVG 3Y
0.24
DEBT TO EQUITY RATIO AVG 5Y
0.19
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-32.55%
CURRENT VS 3Y AVG
-37.34%
CURRENT VS 5Y AVG
-20.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 475 covered companies
CURRENT VS SECTOR MEDIAN
+6.45%
vs the sector median at left
Century Therapeutics, Inc.
Market Cap
$266.18M
Debt to Equity Ratio
0.15
TTM Avg
0.22
3Y Avg
0.24
5Y Avg
0.19
Market Cap
$264.62M
Debt to Equity Ratio
0.03
TTM Avg
0.06
3Y Avg
0.07
5Y Avg
0.04
Market Cap
$261.64M
Debt to Equity Ratio
0.17
TTM Avg
0.17
3Y Avg
0.15
5Y Avg
0.12
Market Cap
$263.26M
Debt to Equity Ratio
0.13
TTM Avg
0.07
3Y Avg
0.16
5Y Avg
0.51
Market Cap
$266.71M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$259.47M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
1.47
5Y Avg
1.27
Market Cap
$280.84M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$277.81M
Debt to Equity Ratio
0.04
TTM Avg
0.11
3Y Avg
0.22
5Y Avg
0.26
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $266.18M | 0.15 | 0.22 | 0.24 | 0.19 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | 0.03 | 0.06 | 0.07 | 0.04 |
| Anika Therapeutics, Inc. (ANIK)vs › | $261.64M | 0.17 | 0.17 | 0.15 | 0.12 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.26M | 0.13 | 0.07 | 0.16 | 0.51 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.71M | 0.00 | 0.00 | 0.02 | 0.02 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.47M | 0.01 | 0.00 | 1.47 | 1.27 |
| AC Immune S.A. (ACIU)vs › | $274.28M | 0.12 | 0.08 | 0.05 | 0.04 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $280.84M | 0.00 | 0.01 | 0.01 | 0.01 |
| Aurora Cannabis Inc. (ACB)vs › | $277.81M | 0.04 | 0.11 | 0.22 | 0.26 |
| Fate Therapeutics, Inc. (FATE)vs › | $282.07M | 0.49 | 0.33 | 0.29 | 0.26 |
Debt/Equity
0.15
Current Ratio
8.28
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.15 |
| 2026-03-31 | 0.18 |
| 2025-12-31 | 0.27 |
| 2025-09-30 | 0.25 |
| 2025-06-30 | 0.25 |
| 2025-03-31 | 0.22 |
| 2024-12-31 | 0.33 |
| 2024-09-30 | 0.28 |
| 2024-06-30 | 0.25 |
| 2024-03-31 | 0.26 |
| 2023-12-31 | 0.26 |
| 2023-09-30 | 0.22 |
| 2023-06-30 | 0.17 |
| 2023-03-31 | 0.19 |
| 2022-12-31 | 0.16 |
| 2022-09-30 | 0.14 |
| 2022-06-30 | 0.12 |
| 2022-03-31 | 0.06 |
| 2021-12-31 | 0.06 |
| 2021-09-30 | 0.06 |
| 2021-06-30 | 0.06 |
| 2021-03-31 | -0.27 |
| 2020-12-31 | -0.20 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
